Reviewer’s report

**Title:** MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1

**Version:** 2  **Date:** 2 December 2012

**Reviewer:** Charles Rosser

**Reviewer’s report:**

In this interesting article by Olsson et al. the authors identify MDM2 SNP and p53 mutations in patients with cT1 bladder cancer. As the authors point out, cT1 tumors can be unpredictable. Thus if we had better prognostic markers it would be of great service to providers and patients. The authors report that neither MDM2 SNP or p53 mutation was associated with prognosis, however, mutated p53 and abnormal p16 tumors were noted to have higher rate of tumor progression and shorter time to progression compared to mutated p53 and normal p16. Overall this is a well written, well laid out manuscript. Below is a point-by-point critique of the manuscript.

**TITLE:** No issues

**ABSTRACT:** No issues

**INTRODUCTION:** No issues

**METHODS:** No issues except typically now we grade bladder tumors as low-grade and high-grade not Gr 1, Gr 2 or Gr 3.

**RESULTS:** Consider adding a figure depicting typical IHC staining.

**DISCUSSION:**

No issues

**CONCLUSION:** No issues

**REFERENCES:** No issues

**TABLES:** No issues

**FIGURES:** Could combine Figure 1 and Figure 2 into one figure.

**Level of interest:** An article of outstanding merit and interest in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:

I declare that I have no competing interests